GT Biopharma Inc (NASDAQ: GTBP) reported a net loss of $4.5 million for the second quarter ended June 30, 2026, compared to a net loss of $30.2 million in the same quarter of 2025. The company holds cash and cash equivalents of approximately $5.1 million as of June 30, 2026, which management anticipates will fund operations through the fourth quarter of 2026.

The year-over-year improvement in net loss was driven by non-operational factors rather than operational efficiency. The prior-year quarter included an initial recognition of a Greenshoe Rights liability of $28.7 million, classified as non-cash and non-recurring. This item did not recur in the current quarter. Excluding this one-time charge, the underlying operational loss expanded significantly.

Operating Expense Growth

Total loss from operations widened to $4.5 million in Q2 2026, up from $1.5 million in Q2 2025. This increase reflects higher spending across both research and development and administrative functions.

Research and Development (R&D) expenses rose to $1.1 million from $0.4 million, primarily due to increased materials and production costs associated with clinical trials for candidates GTB-3650 and GTB-5550. Selling, General and Administrative (SG&A) expenses more than tripled to $3.4 million from $1.1 million, driven by higher marketing expenses and legal/consulting fees.

What the Numbers Show

The divergence between the net loss and operating loss highlights the distortion caused by the prior-year accounting entry. While the headline net loss improved by $25.7 million year-over-year, the underlying operational burn rate increased by $3.0 million. SG&A expenses accounted for approximately 76% of total operating losses in Q2 2026 ($3.4 million of $4.5 million), indicating that administrative and marketing costs are currently the dominant driver of cash outflow, surpassing direct R&D spend.

Clinical Pipeline Updates

The company continues to advance its proprietary TriKE™ platform, with two Phase 1 trials currently enrolling patients.

• GTB-3650: The Phase 1 dose escalation study for CD33-positive leukemias has completed Cohort 4, with Cohort 5 enrollment in progress. An update is anticipated in the second half of 2026. The trial may continue up to Cohort 7, evaluating up to 14 patients.
• GTB-5550: The Phase 1 basket trial for B7-H3 positive solid tumors initiated patient dosing in May 2026. Cohort 1 enrollment is complete, and Cohort 2 is underway. This candidate utilizes subcutaneous dosing. An update is also expected in the second half of 2026.

Michael Breen, Executive Chairman and CEO, stated that discovery efforts remain productive, with the anticipation of announcing IND clearance for an additional pipeline asset in 2026.

GT Biopharma, Inc. has dosed the first patient in a Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager designed for solid tumors. This milestone, announced on May 14, 2026, marks the third drug candidate from the company's proprietary TriKE platform to enter human testing. The move represents GT Biopharma's expansion beyond blood cancers into the larger solid-tumor market, a strategic shift that could significantly alter its risk profile and potential market opportunity if successful.

The company's active clinical programs now consist of GTB-3650 and GTB-5550. GTB-3550, an earlier clinical candidate, has been replaced by the second-generation GTB-3650. GT Biopharma is a clinical-stage immuno-oncology company developing therapeutics based on its TriKE (tri-specific killer engager) platform, which is licensed from the University of Minnesota. The platform aims to connect NK cells to specific cancer targets while delivering an interleukin-15 signal to support NK-cell expansion and persistence.

Pipeline Overview

GT Biopharma's pipeline spans hematologic malignancies, solid tumors, and earlier-stage work in autoimmune disease. The lead active program, GTB-3650, is a second-generation, camelid-nanobody TriKE currently in a Phase 1 dose-escalation trial for relapsed or refractory CD33-expressing hematologic malignancies, specifically acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

The newest entrant, GTB-5550, targets B7-H3, a marker expressed on the surface of various advanced solid tumors. It is being evaluated in a Phase 1 dose-escalation basket trial, which allows the company to test the drug across multiple tumor types under a single protocol. Behind these programs is GTB-7550, an earlier-stage candidate for CD19-positive lymphoid malignancies and autoimmune disease.

Strategic and Market Context

The progression of GTB-5550 into human testing is strategically significant because solid tumors represent the majority of cancer cases, a sector where cell-based immunotherapies have historically faced challenges. The B7-H3 target is attractive due to its broad expression across solid tumors and limited expression in healthy tissue. The basket trial design is intended to allow efficient early signal detection across different cancer types without committing to a single indication immediately.

Despite advancing three TriKE candidates into the clinic, GT Biopharma's market capitalization remains modest compared to many clinical-stage oncology peers. This valuation gap presents a speculative setup where clinical success could drive significant upside, though the company faces the perennial financing risks associated with clinical-stage biotech development. Michael Breen serves as Executive Chairman and Chief Executive Officer.

Platform Evolution and Peer Landscape

The TriKE platform has evolved through technical generations. GTB-3550 served as an initial proof-of-concept, while GTB-3650 incorporates camelid-nanobody technology to improve binding to the CD16 receptor on NK cells. GTB-5550 extends this second-generation engineering to the B7-H3 target. This progression suggests repeatable platform engineering rather than a single asset.

GT Biopharma operates alongside companies such as Nkarta, Inc., Iovance Biotherapeutics, Inc., Fate Therapeutics, Inc., and ImmunityBio, Inc. in the NK-cell and immuno-oncology space. The company distinguishes itself through the number of TriKE candidates it has moved into human testing relative to its size and its current valuation. However, clinical outcomes remain unproven, and future data will be critical for the company's trajectory.